Abstract:Despite recent advances in frontline therapy for diffuse large B-cell lymphoma (DLBCL), at least a third of those diagnosed still will require second or further lines for relapsed or refractory (rel/ref) disease. A small minority of these can be cured with standard chemoimmunotherapy/stem-cell transplant salvage approaches. CD19-directed chimeric antigen receptor T-cell (CAR-19) therapies are increasingly altering the prognostic landscape for rel/ref patients with DLBCL and related aggressive B-cell non-Hodgkin lymphomas. Long-term follow up data show ongoing disease-free outcomes consistent with cure in 30–40% after CAR-19, including high-risk patients primary refractory to or relapsing within 1 year of frontline treatment. This has made CAR-19 a preferred option for these difficult-to-treat populations. Widespread adoption, however, remains challenged by logistical and patient-related hurdles, including a requirement for certified tertiary care centers concentrated in urban centers, production times of at least 3–4 weeks, and high per-patients costs similar to allogeneic bone-marrow transplantation. Bispecific antibodies (BsAbs) are molecular biotherapies designed to bind and activate effector T-cells and drive them to B-cell antigens, leading to a similar cellular-dependent cytotoxicity as CAR-19. May and June of 2023 saw initial approvals of next-generation BsAbs glofitamab and epcoritamab in DLBCL as third or higher-line therapy, or for patients ineligible for CAR-19. BsAbs have similar spectrum but generally reduced severity of immune related side effects as CAR-19 and can be administered in community settings without need to manufacture patient-specific cellular products. To date and in contrast to CAR-19, however, there is no convincing evidence of cure after BsAbs monotherapy, though follow up is limited. The role of BsAbs in DLBCL treatment is rapidly evolving with trials investigating use in both relapsed and frontline curative-intent combinations. The future of DLBCL treatment is bound increasingly to include effector cell mediated immunotherapies, but further optimization of both cellular and BsAb approaches is needed.

Taking a BiTE out of Lymphoma: Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma

Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives

Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns and opportunities

Bispecific Antibody Treatment of Multiple Myeloma: Latest Updates from the 2022 ASH Annual Meeting

Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma

Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas

The Evolving Role of Bispecific Antibodies in Diffuse Large B-Cell Lymphoma

Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs

Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma

Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma

Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies

ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma

Blinatumomab: a novel therapy for the treatment of non-Hodgkin's lymphoma

Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas

Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting

An An Overview of the Treatment of Non-Hodgkin Lymphoma with The Novel Cellular Therapies: CAR-T and Bispecific Monoclonal Antibodies

T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions

Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?

Recent advances and future perspectives of T-cell engagers in lymphoid malignancies

Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies